Reports for APOTEX INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
25 (7%)
Discontinued:
342 (93%)
Reversed:
0 (0%)
367
146 (4%)
70 (29%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-CANDESARTAN | 16MG | TABLET | Actual shortage | 2022-08-12 | 2022-08-12 | 166595 |
| APO-CANDESARTAN | 16MG | TABLET | Resolved | 2021-05-14 | 2021-07-30 | 139406 |
| APO-CANDESARTAN | 32MG | TABLET | Actual shortage | 2021-10-22 | 2021-10-22 | 147815 |
| APO-CANDESARTAN | Resolved | 2020-03-09 | 2020-05-04 | 108228 | ||
| APO-CANDESARTAN | 8MG | TABLET | Resolved | 2020-04-13 | 2020-10-19 | 111895 |
| APO-CANDESARTAN | 32MG | TABLET | Resolved | 2020-05-13 | 2020-09-21 | 114928 |
| APO-CANDESARTAN | 16MG | TABLET | Resolved | 2020-06-24 | 2021-06-14 | 118761 |
| APO-CANDESARTAN | 16MG | TABLET | Resolved | 2020-06-24 | 2020-09-21 | 118763 |
| APO-CANDESARTAN | 4MG | TABLET | Resolved | 2017-08-08 | 2020-02-25 | 18517 |
| APO-CANDESARTAN | 8MG | TABLET | Resolved | 2017-08-08 | 2020-02-25 | 18520 |
| APO-CANDESARTAN | 16MG | TABLET | Resolved | 2017-03-11 | 2017-06-27 | 639 |
| APO-CANDESARTAN | 4MG | TABLET | Resolved | 2017-03-12 | 2018-09-09 | 706 |
| APO-CANDESARTAN | 32MG | TABLET | Resolved | 2017-03-20 | 2020-02-25 | 3516 |
| APO-CANDESARTAN TABLETS | 16MG | TABLET | Resolved | 2024-09-20 | 2025-03-07 | 238233 |
| APO-CANDESARTAN TABLETS | 4MG | TABLET | Resolved | 2024-10-04 | 2025-01-17 | 239355 |
| APO-CANDESARTAN TABLETS | 4MG | TABLET | Resolved | 2024-10-04 | 2024-12-06 | 239358 |
| APO-CANDESARTAN TABLETS | 16MG | TABLET | Resolved | 2024-12-12 | 2025-03-07 | 245502 |
| APO-CANDESARTAN TABLETS | 8MG | TABLET | Resolved | 2025-01-30 | 2025-03-14 | 249077 |
| APO-CANDESARTAN TABLETS | 16MG | TABLET | Resolved | 2025-03-20 | 2025-04-11 | 253078 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Resolved | 2017-09-07 | 2018-02-26 | 21199 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-HYDROMORPHONE CR | 3MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110956 |
| APO-HYDROMORPHONE CR | 6MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110959 |
| APO-HYDROMORPHONE CR | 24MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110968 |
| APO-HYDROMORPHONE CR | 18MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110965 |
| APO-HYDROMORPHONE CR | 12MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110962 |
| APO-HYDROMORPHONE CR | 30MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110971 |
| APO-HYDROXYQUINE | 200MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60524 |
| APO-IMIQUIMOD | Discontinued | 2019-11-26 | 2019-11-26 | 99672 | ||
| APO-IRBESARTAN | 75MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71231 |
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71234 |
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60536 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60539 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71237 |
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-02-23 | 40757 |
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-07-17 | 40760 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-02-23 | 2018-07-17 | 40763 | ||
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40766 |
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40769 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-09-07 | 2018-09-15 | 60548 | ||
| APO-LAMIVUDINE | 150MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60557 |